Compare VTOL & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTOL | INBX |
|---|---|---|
| Founded | 1948 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.7M |
| IPO Year | 2011 | 2024 |
| Metric | VTOL | INBX |
|---|---|---|
| Price | $46.00 | $58.33 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $58.00 | N/A |
| AVG Volume (30 Days) | ★ 173.9K | 143.2K |
| Earning Date | 05-05-2026 | 03-19-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 34.58 | N/A |
| EPS | ★ 4.32 | N/A |
| Revenue | ★ $1,490,512,000.00 | $1,300,000.00 |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $10.71 | ★ N/A |
| Revenue Growth | 5.30 | ★ 550.00 |
| 52 Week Low | $25.11 | $10.81 |
| 52 Week High | $49.55 | $94.57 |
| Indicator | VTOL | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 33.28 |
| Support Level | $42.83 | $28.54 |
| Resistance Level | $46.36 | $85.97 |
| Average True Range (ATR) | 1.21 | 4.27 |
| MACD | 0.17 | -0.55 |
| Stochastic Oscillator | 88.03 | 8.45 |
Bristow Group Inc is the provider of vertical flight solutions. The group provides aviation services to a broad base of offshore energy companies and government entities. Its business comprises three reportable segments: Offshore Energy Services, Government Services, and Other Services. Its customers in Australia, Brazil, Canada, Chile, the Dutch Caribbean, the Falkland Islands, India, Ireland, the Kingdom of Saudi Arabia, Mexico, the Netherlands, Nigeria, Norway, Spain, Suriname, Trinidad, the UK, and the U.S. offshore energy customers use services to transport personnel to, from and between offshore energy installations.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.